Fondaparinux Dosing in ACS and DVT Prophylaxis
For acute coronary syndrome (ACS), use fondaparinux 2.5 mg subcutaneously once daily, starting after hemostasis is established; for DVT prophylaxis post-surgery, use the same 2.5 mg daily dose starting 6-8 hours after surgery; and for DVT treatment, use weight-based dosing: 5 mg (<50 kg), 7.5 mg (50-100 kg), or 10 mg (>100 kg) once daily. 1, 2
Acute Coronary Syndrome Dosing
Initial Therapy
- Dose: 2.5 mg subcutaneous once daily 1
- This is a fixed dose regardless of body weight for ACS patients
- For patients receiving fibrinolytic therapy: give 2.5 mg IV initially, then 2.5 mg subcutaneous daily starting the following day 1
Critical Contraindication
Do not use fondaparinux to support PCI procedures - it carries a Class 3 Harm recommendation due to increased risk of catheter thrombosis (0.9% vs 0.3% with enoxaparin) 1. If your patient is going to the catheterization lab, switch to UFH or bivalirudin.
Renal Dosing
Fondaparinux is contraindicated if creatinine clearance <30 mL/min 1, 2. This is absolute - do not attempt dose reduction; choose an alternative anticoagulant like UFH or enoxaparin with appropriate renal dosing.
Evidence Base
The OASIS-5 trial demonstrated that fondaparinux was similar to enoxaparin for ischemic events at 9 days but reduced major bleeding in NSTE-ACS patients 1. This favorable bleeding profile makes it particularly attractive for medically managed ACS patients who are not proceeding to immediate PCI.
DVT Prophylaxis (Post-Surgical)
Standard Surgical Prophylaxis
- Dose: 2.5 mg subcutaneous once daily 2
- Timing: Start 6-8 hours after surgery, only after hemostasis is established 2
- Starting earlier than 6 hours significantly increases major bleeding risk - this is a critical safety consideration
Duration by Surgery Type
- Hip/knee replacement surgery: 5-9 days (up to 11 days studied) 2
- Hip fracture surgery: 5-9 days initial + up to 24 additional days extended prophylaxis (total 32 days) 2
- Abdominal surgery: 5-9 days (up to 10 days studied) 2
The extended prophylaxis for hip fracture patients reflects their prolonged immobility and higher thrombotic risk compared to elective joint replacement.
DVT Treatment (Acute Symptomatic)
Weight-Based Treatment Dosing
This is fundamentally different from prophylaxis - you must use weight-based dosing: 2
- <50 kg: 5 mg once daily
- 50-100 kg: 7.5 mg once daily
- >100 kg: 10 mg once daily
Bridging to Warfarin
- Start warfarin within 72 hours of fondaparinux initiation 2
- Continue fondaparinux for at least 5 days AND until INR is 2-3 2
- Duration typically 5-9 days (up to 26 days studied) 2
Special Consideration for Low Body Weight
Research shows that patients <50 kg may have higher anti-Factor Xa activity after the second dose (0.53 vs 0.44 mg/L), though still within expected therapeutic range 3. Monitor these patients more closely for bleeding, though dose adjustment is not routinely recommended based on current evidence.
Critical Safety Considerations
Absolute Contraindications
Neuraxial Anesthesia Warning
Epidural/spinal hematoma risk is significant - optimal timing between fondaparinux administration and neuraxial procedures is unknown 2. Consider alternative anticoagulants with more predictable pharmacokinetics (like enoxaparin) if neuraxial anesthesia is planned.
No Reversal Agent Available
Unlike UFH (protamine) or warfarin (vitamin K), fondaparinux has no specific antidote 4. Dialysis may partially remove the drug in overdose situations 4. This lack of reversibility should factor into your decision-making for high-bleeding-risk patients.
Administration Technique
- Subcutaneous injection only - never intramuscular 2
- Inject into fatty tissue of anterolateral or posterolateral abdominal wall, alternating sites 2
- Do not expel air bubble from prefilled syringe before injection 2
- Single-dose prefilled syringes - discard unused portion 2
Common Pitfalls to Avoid
- Using fondaparinux during PCI - this is explicitly contraindicated due to catheter thrombosis risk 1
- Starting too early post-surgery - wait at least 6-8 hours after hemostasis is established 2
- Using prophylactic dose (2.5 mg) for DVT treatment - must use weight-based therapeutic dosing 2
- Ignoring renal function - CrCl <30 mL/min is an absolute contraindication 1, 2
- Forgetting it's once daily - unlike enoxaparin's twice-daily dosing for ACS, fondaparinux is always once daily 1, 2
The 2025 ACC/AHA guidelines position fondaparinux as a reasonable option for medically managed ACS patients, particularly when bleeding risk is a concern, but emphasize switching to UFH or bivalirudin if PCI becomes necessary 1.